{"transactions":[{"id":3340090,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":1161,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":112617},"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340089,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":1746,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":169602},"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340088,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":3,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":291},"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340087,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":106,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10282},"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340086,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"other","acquired":false,"shares":539337,"price":3,"value":1618011.0,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The indicated number of shares is reflective of all common shares held at the Effective Time of the merger, including those shares of Preferred Stock that were converted to common shares of the issuer, pursuant to the terms detailed in Footnotes 2 and 3."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340085,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":112617,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":539337,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340084,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"other","acquired":false,"shares":1324328,"price":3,"value":3972984.0,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The indicated number of shares is reflective of all common shares held at the Effective Time of the merger, including those shares of Preferred Stock that were converted to common shares of the issuer, pursuant to the terms detailed in Footnotes 2 and 3."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340083,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":169602,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1324328,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340082,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"other","acquired":false,"shares":2453,"price":3,"value":7359.0,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The indicated number of shares is reflective of all common shares held at the Effective Time of the merger, including those shares of Preferred Stock that were converted to common shares of the issuer, pursuant to the terms detailed in Footnotes 2 and 3."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340081,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":291,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2453,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340080,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"other","acquired":false,"shares":80160,"price":3,"value":240480.0,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The indicated number of shares is reflective of all common shares held at the Effective Time of the merger, including those shares of Preferred Stock that were converted to common shares of the issuer, pursuant to the terms detailed in Footnotes 2 and 3."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among the issuer, Castle Creek Pharmaceutical Holdings, Inc. (\"Castle Creek\") and Castle Creek Merger Corp. (\"Merger Sub\"), effective as of immediately prior to the effective time of the merger of the issuer and Merger Sub (the \"Effective Time\"), each share of common stock of the issuer that was issued and outstanding immediately prior to the Effective Time, was converted into and thereafter represented the right to receive $3.00 in cash, without interest (the \"Merger Consideration\"), subject to any withholding of taxes required by applicable law, upon surrender of the certificates or book-entry shares in accordance with Section 2.2 of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3340079,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T17:58:10.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":10282,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock of the issuer issued and outstanding immediately prior to the Effective Time (\"Preferred Stock\"), in accordance with the terms of the Certificate of Designations, survived the merger transaction and  thereafter only represented the right to receive an amount in cash, without interest, equal to the conversion amount, as that term is defined in the Consent and Termination Agreement (\"Termination Agreement\") entered into on September 12, 2019 by and among the issuer, Castle Creek, Merger Sub, Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\"), subject to any withholding of taxes required by applicable law, upon delivery of a Notice of Conversion in accordance with Section 2.2 of the Merger Agreement and the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Termination Agreement:  (i) the Conversion Amount was calculated as: (x) the number of issuer shares of common stock such share of Preferred Stock is entitled to be converted into pursuant to the Certificate of Designation, based on the stated value and assuming a conversion price of $11.6355, multiplied by (y) the Merger Consideration; and (ii) the Merger Sub issued and delivered a Promissory Note in the principal amount equal to the aggregate amount of all of the Conversion Amounts which such securityholder is entitled to receive.  The Promissory Notes bear interest at a rate of 8% per annum and Merger Sub shall repay the principal amount and all accrued and unpaid interest on the date that is one hundred-eighty (180) days following the closing date of the merger transaction.  Each entity received the noted Conversion Amount and Promissory Notes:  Kapital Joe ($30,846); Mascara Kaboom ($873); NRM VII Holdings ($508,086); and Intrexon ($337,851)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls Kapital Joe, Mascara Kaboom, and NRM VII Holdings. Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":80160,"source":{"system":"sec-edgar","filing":"0001567619-19-023283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000156761919023283/doc1.xml","form_type":"4"}},{"id":3566517,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:13:53.000Z","date":"2019-04-03","kind":"sale","acquired":false,"shares":69161,"price":0.65,"value":44954.65,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The indicated share amount is reflective of a 1:35 reverse stock split effected by the issuer on August 10, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":165332,"source":{"system":"sec-edgar","filing":"0001567619-19-008334","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/doc1.xml","form_type":"4"}},{"id":3566516,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:13:53.000Z","date":"2019-04-03","kind":"sale","acquired":false,"shares":26080,"price":0.65,"value":16952.0,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The indicated share amount is reflective of a 1:35 reverse stock split effected by the issuer on August 10, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":62342,"source":{"system":"sec-edgar","filing":"0001567619-19-008334","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/doc1.xml","form_type":"4"}},{"id":3566515,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:13:53.000Z","date":"2019-04-02","kind":"sale","acquired":false,"shares":9909,"price":0.66,"value":6539.94,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The indicated share amount is reflective of a 1:35 reverse stock split effected by the issuer on August 10, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":234493,"source":{"system":"sec-edgar","filing":"0001567619-19-008334","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/doc1.xml","form_type":"4"}},{"id":3566514,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:13:53.000Z","date":"2019-04-02","kind":"sale","acquired":false,"shares":3737,"price":0.66,"value":2466.42,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The indicated share amount is reflective of a 1:35 reverse stock split effected by the issuer on August 10, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":88422,"source":{"system":"sec-edgar","filing":"0001567619-19-008334","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/doc1.xml","form_type":"4"}},{"id":3566513,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:13:53.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":30265,"price":0.67,"value":20277.55,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The indicated share amount is reflective of a 1:35 reverse stock split effected by the issuer on August 10, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":244402,"source":{"system":"sec-edgar","filing":"0001567619-19-008334","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/doc1.xml","form_type":"4"}},{"id":3566512,"issuer":{"id":7919,"kind":"organization","name":"Theriva Biologics, Inc."},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T21:13:53.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":11413,"price":0.67,"value":7646.71,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The indicated share amount is reflective of a 1:35 reverse stock split effected by the issuer on August 10, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":92159,"source":{"system":"sec-edgar","filing":"0001567619-19-008334","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/doc1.xml","form_type":"4"}},{"id":3695743,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-15T17:21:42.000Z","date":"2019-01-15","kind":"sale","acquired":false,"shares":345897,"price":0.15,"value":51884.55,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon Corporation (\"Intrexon\") and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1692366,"source":{"system":"sec-edgar","filing":"0001567619-19-001160","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761919001160/doc1.xml","form_type":"4"}},{"id":3695742,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-15T17:21:42.000Z","date":"2019-01-14","kind":"sale","acquired":false,"shares":400507,"price":0.16,"value":64081.12,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon Corporation (\"Intrexon\") and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2038263,"source":{"system":"sec-edgar","filing":"0001567619-19-001160","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761919001160/doc1.xml","form_type":"4"}},{"id":3695741,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-15T17:21:42.000Z","date":"2019-01-11","kind":"sale","acquired":false,"shares":251800,"price":0.17,"value":42806.0,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon Corporation (\"Intrexon\") and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2438770,"source":{"system":"sec-edgar","filing":"0001567619-19-001160","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761919001160/doc1.xml","form_type":"4"}},{"id":3781946,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2018-10-29T16:21:23.000Z","date":"2018-10-25","kind":"other","acquired":false,"shares":1538461,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 24, 2018, Intrexon Corporation (\"Intrexon\") entered into a Warrant Exercise Agreement with the issuer, pursuant to which, on October 25, 2018, Intrexon exercised its warrant to purchase 1,538,461 shares of common stock, for a purchase price of $3,076,922 or $2.00 per share, which exercise price was reduced in accordance with the terms of the warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 24, 2018, Intrexon Corporation (\"Intrexon\") entered into a Warrant Exercise Agreement with the issuer, pursuant to which, on October 25, 2018, Intrexon exercised its warrant to purchase 1,538,461 shares of common stock, for a purchase price of $3,076,922 or $2.00 per share, which exercise price was reduced in accordance with the terms of the warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":2,"exercise_date":"2018-01-17","expiration_date":"2023-01-17","underlying":"Common Stock","underlying_shares":1538461},"source":{"system":"sec-edgar","filing":"0001567619-18-004696","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761918004696/doc1.xml","form_type":"4"}},{"id":3781945,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-29T16:21:23.000Z","date":"2018-10-25","kind":"other","acquired":true,"shares":1538461,"price":2,"value":3076922.0,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 24, 2018, Intrexon Corporation (\"Intrexon\") entered into a Warrant Exercise Agreement with the issuer, pursuant to which, on October 25, 2018, Intrexon exercised its warrant to purchase 1,538,461 shares of common stock, for a purchase price of $3,076,922 or $2.00 per share, which exercise price was reduced in accordance with the terms of the warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 24, 2018, Intrexon Corporation (\"Intrexon\") entered into a Warrant Exercise Agreement with the issuer, pursuant to which, on October 25, 2018, Intrexon exercised its warrant to purchase 1,538,461 shares of common stock, for a purchase price of $3,076,922 or $2.00 per share, which exercise price was reduced in accordance with the terms of the warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":8239199,"source":{"system":"sec-edgar","filing":"0001567619-18-004696","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761918004696/doc1.xml","form_type":"4"}},{"id":3795185,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-10-09T19:54:52.000Z","date":"2018-10-05","kind":"other","acquired":false,"shares":130849,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (\"Intrexon\"), entered into a definitive license agreement to replace all existing agreements between the companies.  In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (\"Intrexon\"), entered into a definitive license agreement to replace all existing agreements between the companies.  In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (\"Intrexon\"), entered into a definitive license agreement to replace all existing agreements between the companies.  In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (\"Intrexon\"), entered into a definitive license agreement to replace all existing agreements between the companies.  In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (\"Intrexon\"), entered into a definitive license agreement to replace all existing agreements between the companies.  In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001567619-18-003898","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761918003898/doc1.xml","form_type":"4"}},{"id":3806027,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-09-28T17:29:39.000Z","date":"2018-09-28","kind":"other","acquired":true,"shares":1295,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":130849,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001567619-18-003286","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761918003286/doc1.xml","form_type":"4"}},{"id":3829036,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-08-31T19:02:53.000Z","date":"2018-08-31","kind":"other","acquired":true,"shares":1282,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":129554,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001567619-18-002002","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000156761918002002/doc1.xml","form_type":"4"}},{"id":3858142,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-07-31T17:03:56.000Z","date":"2018-07-31","kind":"other","acquired":true,"shares":1270,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":128272,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-034561","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118034561/doc1.xml","form_type":"4"}},{"id":3880734,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-06-29T16:28:21.000Z","date":"2018-06-29","kind":"other","acquired":true,"shares":1257,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":127002,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-030717","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118030717/doc1.xml","form_type":"4"}},{"id":3909161,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-06-04T16:21:51.000Z","date":"2018-05-31","kind":"other","acquired":true,"shares":1245,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":125745,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-027082","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118027082/doc1.xml","form_type":"4"}},{"id":3953981,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-04-30T16:11:00.000Z","date":"2018-04-30","kind":"other","acquired":true,"shares":1232,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":124500,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-020491","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118020491/doc1.xml","form_type":"4"}},{"id":3978903,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-03-30T17:01:52.000Z","date":"2018-03-29","kind":"other","acquired":true,"shares":1220,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":123268,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-016245","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118016245/doc1.xml","form_type":"4"}},{"id":4028226,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-02-28T16:54:14.000Z","date":"2018-02-28","kind":"other","acquired":true,"shares":1208,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":122048,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-010836","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118010836/doc1.xml","form_type":"4"}},{"id":4083804,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-01-31T19:33:52.000Z","date":"2018-01-31","kind":"other","acquired":true,"shares":1196,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":120840,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-004247","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118004247/doc1.xml","form_type":"4"}},{"id":4094830,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2018-01-19T17:19:03.000Z","date":"2018-01-17","kind":"purchase","acquired":true,"shares":1538461,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The indicated number of warrants to purchase common stock of the issuer were received in connection with the purchase of common stock in an underwritten public offering of the issuer, which closed on January 17, 2018 (the \"Offering\").  In the Offering, each share of common stock was sold together with a warrant to purchase one share of common stock at a combined effective price of $3.25 per share and accompanying common warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon Corporation (\"Intrexon\") and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1538461,"derivative":{"exercise_price":3.25,"exercise_date":"2018-01-17","expiration_date":"2023-01-17","underlying":"Common Stock","underlying_shares":1538461},"source":{"system":"sec-edgar","filing":"0001140361-18-002633","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118002633/doc1.xml","form_type":"4"}},{"id":4094829,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-19T17:19:03.000Z","date":"2018-01-17","kind":"purchase","acquired":true,"shares":1538461,"price":3.25,"value":4999998.25,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon Corporation (\"Intrexon\") and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":6700738,"source":{"system":"sec-edgar","filing":"0001140361-18-002633","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118002633/doc1.xml","form_type":"4"}},{"id":4113674,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-01-03T17:54:00.000Z","date":"2017-12-29","kind":"other","acquired":true,"shares":1184,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":119644,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-18-000538","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118000538/doc1.xml","form_type":"4"}},{"id":4113673,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-01-03T17:54:00.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant will vest in full and become exercisable on the first anniversary of the date of grant or earlier in the event of a change of control of the issuer."}],"balance_after":25000,"derivative":{"exercise_price":4.14,"expiration_date":"2027-12-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001140361-18-000538","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036118000538/doc1.xml","form_type":"4"}},{"id":4134159,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-12-13T17:28:11.000Z","date":"2017-12-11","kind":"purchase","acquired":true,"shares":4805,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The indicated number of warrants to purchase common stock of the issuer were received in connection with the purchase of common stock in an underwritten public offering of the issuer, which closed on December 11, 2017 (the \"Offering\").  In the Offering, each share of common stock was sold together with a common warrant to purchase one share of common stock at a combined effective price of $0.77 per share and accompanying common warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":4805,"derivative":{"exercise_price":0.77,"exercise_date":"2017-12-11","expiration_date":"2022-12-11","underlying":"Common Stock","underlying_shares":4805},"source":{"system":"sec-edgar","filing":"0001140361-17-046077","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117046077/doc1.xml","form_type":"4"}},{"id":4134158,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-12-13T17:28:11.000Z","date":"2017-12-11","kind":"purchase","acquired":true,"shares":155347,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The indicated number of warrants to purchase common stock of the issuer were received in connection with the purchase of common stock in an underwritten public offering of the issuer, which closed on December 11, 2017 (the \"Offering\").  In the Offering, each share of common stock was sold together with a common warrant to purchase one share of common stock at a combined effective price of $0.77 per share and accompanying common warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":155347,"derivative":{"exercise_price":0.77,"exercise_date":"2017-12-11","expiration_date":"2022-12-11","underlying":"Common Stock","underlying_shares":155347},"source":{"system":"sec-edgar","filing":"0001140361-17-046077","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117046077/doc1.xml","form_type":"4"}},{"id":4134157,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-12-13T17:28:11.000Z","date":"2017-12-11","kind":"purchase","acquired":true,"shares":2567121,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The indicated number of warrants to purchase common stock of the issuer were received in connection with the purchase of common stock in an underwritten public offering of the issuer, which closed on December 11, 2017 (the \"Offering\").  In the Offering, each share of common stock was sold together with a common warrant to purchase one share of common stock at a combined effective price of $0.77 per share and accompanying common warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2567121,"derivative":{"exercise_price":0.77,"exercise_date":"2017-12-11","expiration_date":"2022-12-11","underlying":"Common Stock","underlying_shares":2567121},"source":{"system":"sec-edgar","filing":"0001140361-17-046077","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117046077/doc1.xml","form_type":"4"}},{"id":4134156,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T17:28:11.000Z","date":"2017-12-11","kind":"purchase","acquired":true,"shares":4805,"price":0.77,"value":3699.85,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The indicated number of common shares is reflective of a 1-for-3 reverse stock split effected by the issuer on March 13, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":10806,"source":{"system":"sec-edgar","filing":"0001140361-17-046077","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117046077/doc1.xml","form_type":"4"}},{"id":4134155,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T17:28:11.000Z","date":"2017-12-11","kind":"purchase","acquired":true,"shares":155347,"price":0.77,"value":119617.19,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The indicated number of common shares is reflective of a 1-for-3 reverse stock split effected by the issuer on March 13, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":349386,"source":{"system":"sec-edgar","filing":"0001140361-17-046077","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117046077/doc1.xml","form_type":"4"}},{"id":4134154,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T17:28:11.000Z","date":"2017-12-11","kind":"purchase","acquired":true,"shares":2567121,"price":0.77,"value":1976683.17,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The indicated number of common shares is reflective of a 1-for-3 reverse stock split effected by the issuer on March 13, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":5773626,"source":{"system":"sec-edgar","filing":"0001140361-17-046077","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117046077/doc1.xml","form_type":"4"}},{"id":4147979,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-11-30T19:59:34.000Z","date":"2017-11-30","kind":"other","acquired":true,"shares":1172,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":118460,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-044516","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117044516/doc1.xml","form_type":"4"}},{"id":4176664,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-11-01T16:16:25.000Z","date":"2017-10-31","kind":"other","acquired":true,"shares":1161,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":117288,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-040505","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117040505/doc1.xml","form_type":"4"}},{"id":4199441,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-09-29T16:42:22.000Z","date":"2017-09-29","kind":"other","acquired":true,"shares":1149,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":116127,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-036971","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117036971/doc1.xml","form_type":"4"}},{"id":4220944,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-08-31T20:37:22.000Z","date":"2017-08-31","kind":"other","acquired":true,"shares":1138,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":114978,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-034041","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117034041/doc1.xml","form_type":"4"}},{"id":4248727,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-07-31T17:35:59.000Z","date":"2017-07-31","kind":"other","acquired":true,"shares":1127,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":113840,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-029431","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117029431/doc1.xml","form_type":"4"}},{"id":4251330,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-26T17:30:55.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":124609,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by TSCP V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk controls each of R.J. Kirk DOT, TSCP V, Third Security, LLC, (\"Third Security\"), Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":124609,"source":{"system":"sec-edgar","filing":"0001140361-17-028759","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117028759/doc1.xml","form_type":"4"}},{"id":4251329,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-26T17:30:55.000Z","date":"2017-07-24","kind":"other","acquired":true,"shares":121231,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by R.J. Kirk DOT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk controls each of R.J. Kirk DOT, TSCP V, Third Security, LLC, (\"Third Security\"), Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":200519,"source":{"system":"sec-edgar","filing":"0001140361-17-028759","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117028759/doc1.xml","form_type":"4"}},{"id":4251328,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-26T17:30:55.000Z","date":"2017-07-24","kind":"other","acquired":false,"shares":338816,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by NRM V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 24, 2017, New River Management V, LP (\"NRM V\") made a liquidating distribution of its assets to its partners in connection with the dissolution of the partnership in accordance with the terms of its Limited Partnership Agreement dated May 11, 2007.  NRM V held 338,816 shares of common stock of the issuer.  The following entities in their capacities as partners of NRM V, or designees, received shares:  R.J. Kirk Declaration of Trust (\"R.J. Kirk DOT\") and Third Security Capital Partners V, LLC (\"TSCP V\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk controls each of R.J. Kirk DOT, TSCP V, Third Security, LLC, (\"Third Security\"), Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-17-028759","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117028759/doc1.xml","form_type":"4"}},{"id":4269555,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-06-30T16:24:37.000Z","date":"2017-06-30","kind":"other","acquired":true,"shares":1115,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":112713,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-026872","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117026872/doc1.xml","form_type":"4"}},{"id":4298560,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-06-01T17:23:32.000Z","date":"2017-05-31","kind":"other","acquired":true,"shares":1104,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":111598,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-023343","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117023343/doc1.xml","form_type":"4"}},{"id":4330956,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-04","kind":"other","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The indicated share amount is reflective of a 1:10 reverse stock split effected by the issuer on October 7, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls NRM VII Holdings.  Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2013-06-25","expiration_date":"2018-06-25","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330955,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-08","kind":"sale","acquired":false,"shares":1881,"price":2.54,"value":4777.74,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon.  Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon.  Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":85397,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330954,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-05","kind":"sale","acquired":false,"shares":13893,"price":2.7,"value":37511.1,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon.  Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon.  Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":87278,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330953,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-04","kind":"sale","acquired":false,"shares":2278,"price":2.97,"value":6765.66,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The indicated share amount is reflective of a 1:10 reverse stock split effected by the issuer on October 7, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon.  Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon.  Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":101171,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330952,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-08","kind":"sale","acquired":false,"shares":9695,"price":2.54,"value":24625.3,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls NRM VII Holdings.  Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":440418,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330951,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-05","kind":"sale","acquired":false,"shares":71607,"price":2.7,"value":193338.9,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls NRM VII Holdings.  Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":450113,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330950,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-04","kind":"sale","acquired":false,"shares":11739,"price":2.97,"value":34864.83,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a joint selling program, NRM VII Holdings I, LLC (\"NRM VII Holdings\") and Intrexon Corporation (\"Intrexon\") sold shares on a pro rata basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls NRM VII Holdings.  Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":521720,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330949,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-04","kind":"sale","acquired":false,"shares":49875,"price":4.01,"value":199998.75,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares surrendered to the issuer in order to satisfy the exercise price in connection with the cashless exercise of a warrant to purchase 250,000 shares of common stock of the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls NRM VII Holdings.  Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":533459,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4330948,"issuer":{"id":8067,"kind":"organization","name":"SOLIGENIX, INC.","symbol":"SNGX"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-08T21:30:45.000Z","date":"2017-05-04","kind":"other","acquired":true,"shares":250000,"price":0.8,"value":200000.0,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The indicated share amount is reflective of a 1:10 reverse stock split effected by the issuer on October 7, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls NRM VII Holdings.  Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk.  Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":583334,"source":{"system":"sec-edgar","filing":"0001140361-17-018903","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812796/000114036117018903/doc1.xml","form_type":"4"}},{"id":4338611,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-05-02T12:40:35.000Z","date":"2017-04-28","kind":"other","acquired":true,"shares":1094,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":110494,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-017809","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117017809/doc1.xml","form_type":"4"}},{"id":4367267,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-03-31T17:38:57.000Z","date":"2017-03-31","kind":"other","acquired":true,"shares":1083,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":109400,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-014219","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117014219/doc1.xml","form_type":"4"}},{"id":4391799,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":1496529,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation (\"Intrexon\"). Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1496529,"derivative":{"exercise_price":0.8459,"underlying":"Common Stock","underlying_shares":1496529},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391798,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":2250594,"ownership":{"direct":false,"nature":"by NRM VII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2250594,"derivative":{"exercise_price":0.8459,"underlying":"Common Stock","underlying_shares":2250594},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391797,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":3867,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":3867,"derivative":{"exercise_price":0.8459,"underlying":"Common Stock","underlying_shares":3867},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391796,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":136634,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":136634,"derivative":{"exercise_price":0.8459,"underlying":"Common Stock","underlying_shares":136634},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391795,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":1161,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation (\"Intrexon\"). Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1496529,"derivative":{"exercise_price":0.7757,"underlying":"Common Stock","underlying_shares":1496529},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391794,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":1746,"ownership":{"direct":false,"nature":"by NRM VII"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2250594,"derivative":{"exercise_price":0.7757,"underlying":"Common Stock","underlying_shares":2250594},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391793,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":3,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":3867,"derivative":{"exercise_price":0.7757,"underlying":"Common Stock","underlying_shares":3867},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4391792,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred","published_at":"2017-03-10T15:32:48.000Z","date":"2017-03-08","kind":"purchase","acquired":true,"shares":106,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 7, 2017, the issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with certain of its existing investors pursuant to which the issuer agreed to sell a total of 8,000 units (the \"Units\") for a purchase price of $1,000 per Unit, with each Unit consisting of (i) one share of the issuers Series A Convertible Preferred Stock with an initial stated value of $1,000 and is immediately convertible into 1,289 shares of the issuer's common stock at a conversion price of $0.7757 (\"Preferred Stock\") and (ii) warrants to purchase 1,289 shares of the issuer's common stock. Each warrant will have an exercise price of $0.84591 per share, will be exercisable six months after the date of issuance and will expire five years from the date of issuance.  The Preferred Stock and warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Randal J. Kirk controls Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\") and NRM VII Holdings I, LLC (NRM VII Holdings\"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":136634,"derivative":{"exercise_price":0.7757,"underlying":"Common Stock","underlying_shares":136634},"source":{"system":"sec-edgar","filing":"0001140361-17-011602","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000114036117011602/doc1.xml","form_type":"4"}},{"id":4410810,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-03-02T17:49:44.000Z","date":"2017-02-28","kind":"other","acquired":true,"shares":1072,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":108317,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-010357","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117010357/doc1.xml","form_type":"4"}},{"id":4471619,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2017-02-02T12:02:49.000Z","date":"2017-01-31","kind":"other","acquired":true,"shares":1061,"ownership":{"direct":false,"nature":"by Intrexon"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series 1 Preferred Stock (\"Preferred Stock\") has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock.  The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation (\"Intrexon\") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the \"Issuance Agreement\").  The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly dividend payable in additional shares of Preferred Stock equal to $12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of $1,200, rounded down to the nearest whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":107245,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-004101","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117004101/doc1.xml","form_type":"4"}},{"id":4485552,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":3637,"ownership":{"direct":false,"nature":"by NRM VII Holdings"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":3637,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485551,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":199682,"ownership":{"direct":false,"nature":"by NRM VI Holdings"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":199682,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485550,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":338816,"ownership":{"direct":false,"nature":"by NRM V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":338816,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485549,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":10153,"ownership":{"direct":false,"nature":"by Incentive 2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":10153,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485548,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":20306,"ownership":{"direct":false,"nature":"by Staff 2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":20306,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485547,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":20306,"ownership":{"direct":false,"nature":"by Senior Staff 2008"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":20306,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485546,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":14076,"ownership":{"direct":false,"nature":"by MGK 2011"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":14076,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485545,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":3199,"ownership":{"direct":false,"nature":"by ADC 2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":3199,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485544,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":880,"ownership":{"direct":false,"nature":"by Sr. Staff"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":880,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485543,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":82083,"ownership":{"direct":false,"nature":"by Mascara Kaboom"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":82083,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485542,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":99537,"ownership":{"direct":false,"nature":"by Kapital Joe"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Randal J. Kirk controls each of Kapital Joe, LLC (\"Kapital Joe\"), Mascara Kaboom, LLC (\"Mascara Kaboom\"), Third Security Senior Staff LLC (\"Sr. Staff\"), ADC 2010, LLC (\"ADC 2010\"), MGK 2011, LLC (\"MGK 2011\"), Third Security Senior Staff 2008 LLC (\"Senior Staff 2008\"), Third Security Staff 2010 LLC (\"Staff 2010\"), Third Security Incentive 2010 LLC (\"Incentive 2010\"), New River Management V, LP (\"NRM V\"), NRM VI Holdings I, LLC (\"NRM VI Holdings\") and NRM VII Holdings I, LLC (\"NRM VII Holdings\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":99537,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485541,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":295,"ownership":{"direct":false,"nature":"by Incentive 2006"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":295,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485540,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":885,"ownership":{"direct":false,"nature":"by Staff 2006"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":885,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485539,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":1770,"ownership":{"direct":false,"nature":"by Senior Staff 2006"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1770,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485538,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":2021,"ownership":{"direct":false,"nature":"by Kellie L. Banks LTT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2021,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485537,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":12617,"ownership":{"direct":false,"nature":"by JPK 2012"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":12617,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485536,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":1132,"ownership":{"direct":false,"nature":"by ZSK 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1132,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485535,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":12726,"ownership":{"direct":false,"nature":"by MGK 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":12726,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485534,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":10784,"ownership":{"direct":false,"nature":"by JPK 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":10784,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485533,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":1708,"ownership":{"direct":false,"nature":"by ZSK 2008"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1708,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485532,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":2095,"ownership":{"direct":false,"nature":"by MGK 2008"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2095,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485531,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":2080,"ownership":{"direct":false,"nature":"by JPK 2008"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":2080,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485530,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":20,"ownership":{"direct":false,"nature":"by Lotus"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":20,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485529,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":4659,"ownership":{"direct":false,"nature":"by Staff 2001"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":4659,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485528,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":79288,"ownership":{"direct":false,"nature":"by R.J. Kirk DOT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":79288,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}},{"id":4485527,"issuer":{"id":8187,"kind":"organization","name":"AQUABOUNTY TECHNOLOGIES INC"},"owners":[{"id":55166,"kind":"person","name":"KIRK RANDAL J","position":1,"cik":"0001091823","reported_name":"KIRK RANDAL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":4356,"kind":"organization","name":"PRECIGEN, INC.","symbol":"PGEN","position":2,"cik":"0001356090","reported_name":"INTREXON CORP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-20T16:56:02.000Z","date":"2017-01-18","kind":"other","acquired":true,"shares":5775,"ownership":{"direct":false,"nature":"by Third Security"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Intrexon Corporation (\"Intrexon\") declared a dividend of shares of AquaBounty Technologies, Inc. common stock held by it to its holders of record as of January 9, 2017 (the \"Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Randal J. Kirk controls each of Third Security, R.J. Kirk DOT, Third Security Staff 2001 LLC (\"Staff 2001\"), Lotus Capital (2000) Company Inc. (\"Lotus\"), JPK 2008, LLC (\"JPK 2008\"), MGK 2008, LLC (\"MGK 2008\"), ZSK 2008, LLC (\"ZSK 2008\"), JPK 2009, LLC (\"JPK 2009\"), MGK 2009, LLC (\"MGK 2009\"), ZSK 2009, LLC (\"ZSK 2009\"), JPK 2012, LLC (\"JPK 2012\"), Kellie L. Banks (2009) Long Term Trust (\"Kellie L. Banks LTT\"), Third Security Senior Staff 2006 LLC (\"Senior Staff 2006\"), Third Security Staff 2006 LLC (\"Staff 2006\") and Third Security Incentive 2006 LLC (\"Incentive 2006\"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":5775,"source":{"system":"sec-edgar","filing":"0001140361-17-002429","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091823/000114036117002429/doc1.xml","form_type":"4"}}],"next_cursor":"2017-01-20T16:56:02.000000Z,4485527"}